Studybox Research 510(k) Clinical Studies

Point-of-Care Pregnancy (hCG) Test

Clinical and analytical performance to support substantial equivalence.

Studybox

510(k) Clinical Studies

Urine hCG testing is one of the original CLIA-waived tests, and professional and consumer versions have been cleared for decades. The clinical study compares the qualitative device to a quantitative laboratory hCG assay, with specimens concentrated near the device's claimed detection limit, and establishes clinical performance against confirmed pregnancy outcome. Early pregnancy specimens are the hard part: the study needs women tested in the days around expected menses, when hCG is low and rising, which requires targeted recruitment through fertility care or prospective cycle tracking.

Two analytical issues recur. Urine hCG is partly present as the beta core fragment, which some antibody pairs detect poorly and which can cause false negatives in some urine specimens; and very high hCG concentrations can produce a hook effect in some device formats. Point-of-care devices with a whole blood claim add a specimen type with its own matrix questions, often for emergency department use before imaging or medication.

Analyte: Human chorionic gonadotropin (hCG), qualitative
Therapeutic area: Women's Health
Specimens: Urine, Serum and Plasma, Venous Whole Blood
Intended-use settings: physician office, urgent care, emergency department, pharmacy, home use
Operators: Non-laboratory clinic staff in waived settings; lay users for over-the-counter versions.
Comparator: Typically a quantitative laboratory serum hCG immunoassay, with pregnancy status confirmed by clinical follow-up where the protocol requires it.

510(k) Studies specifics

What Changes for This Assay on This Pathway.

The detection limit claimed in labeling must be supported by specimens whose quantitative hCG falls around it, with agreement reported by concentration band; dilution series of pregnancy urine are typically used to supplement.
Each specimen type is a separate claim; a whole blood or serum claim requires its own comparison and, for whole blood, hematocrit interference data.
Beta core fragment and high-dose hook effect are expected analytical studies, and interference from hCG-producing conditions and medications is addressed in labeling.

Endpoints the study must support

Agreement with the quantitative hCG comparator classified at the device's claimed detection limit, with separate reporting of specimens near the limit
Clinical sensitivity and specificity against confirmed pregnancy status, including early pregnancy around the time of expected menses
Agreement across claimed specimen types (urine, serum, plasma, whole blood)
For over-the-counter claims, lay user agreement and interpretation of results

Enrollment realities

Driven by early pregnancy specimens near the detection limit, which are uncommon in general clinic populations; fertility and prospective-cycle recruitment supply them. Negative and strongly positive specimens accrue quickly.

How Studybox runs it

Pre-Qualified Sites, Embedded Coordinators.

Our 100+ pre-qualified U.S. sites are matched to the intended-use population and setting, with Studybox coordinators embedded on site for recruitment, consent, specimen handling, and data capture. Typical activation is about four weeks. How we run 510(k) clinical studies →

Same assay, other pathways

Relevant FDA guidance

FAQ

Point-of-Care Pregnancy (hCG) Test Study Questions.

01 Who operates the point-of-care pregnancy (hcg) test in a 510(k) studies study?

Non-laboratory clinic staff in waived settings; lay users for over-the-counter versions.

02 What is the comparator for a point-of-care pregnancy (hcg) test study?

Typically a quantitative laboratory serum hCG immunoassay, with pregnancy status confirmed by clinical follow-up where the protocol requires it.

03 What drives enrollment for a point-of-care pregnancy (hcg) test study?

Let's talk IVD research

Planning a point-of-care pregnancy (hcg) test study?

Tell us the intended use and setting. We'll come back with a site plan, operator strategy, and a realistic activation timeline for the 510(k) studies pathway.